血清VEGF水平在非小细胞肺癌综合评价中的作用

Significance of serum vascular endothelial growth factor in non-small cell lung cancer

目的通过检测非小细胞肺癌(NSCLC)患者的血清血管内皮细胞生长因子(sVEGF),探讨sVEGF与NSCLC患者之间的关系及临床意义。方法用酶联免疫吸附法(ELISA)检测69例NSCLC患者和20例健康正常人的sVEGF水平。结果NSCLC患者的sVEGF水平(156.3±17.2)pg/mL显著高于健康正常人(46.6±19.3)pg/mL(P=0.000 0)。sVEGF与患者的年龄、性别、肿瘤大小、初复治组间差异无统计学意义(P>0.05)。鳞癌患者sVEGF表达明显高于腺癌(P=0.029 7),有远处转移NSCLC患者的sVEGF含量显著高于无远处转移的(P=0.000 0)。sVEGF水平与外周血白细胞数、中性粒细胞数和血小板数密切相关(r=0.524,0.634及0.728)。放疗前、结束时和放疗后SD+PD组sVEGF水平分别高于CR+PR组。结论检测NSCLC患者的sVEGF水平,对评估肿瘤负荷、复发转移、疗效均为一项有意义的指标。

Objective To explore the role and significance of serum vascular endothelial growth factor （VEGF） in patients with non-small cell lung cancer （NSCLC）. Methods Serum VEGF was determined by sandwich enzyme linked immuno-adsorbent assay （ELISA） in 69 patients with NSCLC and 20 healthy individuals. Results Serum VEGF level in NSCLC （ 156.3± 17.2） pg/ml was significandy elevated as compared with that in the controls （46.6 ± 19.3）pg/ml（ P = 0. 000 0）. No correlation was found between serum VEGF and gender, age, tumor size or the first-again treatment （ P 〉 0.05）. VEGF in squamous cell carcinoma was significantly higher than that in adenocarcinoma （P = 0.029 7）, and serum VEGF was significantly higher in patients with distant metastasis than those without （ P = 0. 000 0）. Serum VEGF level was closely related to the number of peripheral blood lenkocytes, neutrophils and platelets（ R = 0.524, 0.634 and 0.728）. The level of VEGF was significantly elevated before radiotherapy, right after and after radiotherapy in the SD ＋ PD group compared with the CR ＋ PR group. Conclusion Sertan VEGF level is associated with tumor burden, tumor relapse and metastasis, and therapeutic effectiveness in patients with NSCLC.